Neuromyelitis optica spectrum disorders
- PMID: 22810601
- DOI: 10.1212/01.CON.0000389937.69413.15
Neuromyelitis optica spectrum disorders
Abstract
Neuromyelitis optica is an uncommon inflammatory demyelinating CNS disorder that is distinct from multiple sclerosis with respect to clinical, laboratory, neuroimaging, and prognostic characteristics. Autoantibodies that target aquaporin-4 are highly specific for neuromyelitis optica and have helped define a spectrum of disease beyond the classic definition of acute transverse myelitis and optic neuritis. Accumulating evidence supports the pathogenic potential that these autoantibodies possess in relation to the unique vasculocentric immunopathology of the disease. Current treatment strategies therefore include the use of corticosteroids and plasmapheresis for acute attacks and general or humoral immunosuppression for attack prevention. Ongoing research will focus on establishing the pathogenic mechanisms of the disease, in part derived from newly reported animal models, and testing-focused treatment strategies that evolve from this knowledge.
Similar articles
-
Neuromyelitis optica: a distinct demyelinating disease of the central nervous system.Acta Neurol Scand. 2008 Oct;118(4):209-17. doi: 10.1111/j.1600-0404.2008.01002.x. Epub 2008 Mar 11. Acta Neurol Scand. 2008. PMID: 18336627 Review.
-
Presentation of neuromyelitis optica spectrum disorder after more than twenty years of systemic sclerosis.Mult Scler Relat Disord. 2012 Oct;1(4):202-3. doi: 10.1016/j.msard.2012.04.002. Epub 2012 Jun 20. Mult Scler Relat Disord. 2012. PMID: 25877268
-
Transverse myelitis spectrum disorders.Neurol India. 2009 Mar-Apr;57(2):126-33. doi: 10.4103/0028-3886.51278. Neurol India. 2009. PMID: 19439840 Review.
-
Neuromyelitis optica: new findings on pathogenesis.Int Rev Neurobiol. 2007;79:665-88. doi: 10.1016/S0074-7742(07)79029-3. Int Rev Neurobiol. 2007. PMID: 17531863 Review.
-
Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions.Curr Opin Neurol. 2008 Jun;21(3):366-72. doi: 10.1097/WCO.0b013e3282fd172b. Curr Opin Neurol. 2008. PMID: 18451724 Review.
Cited by
-
Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms.Ann Neurol. 2014 Aug;76(2):168-84. doi: 10.1002/ana.24200. Epub 2014 Jul 10. Ann Neurol. 2014. PMID: 24930434 Free PMC article. Review.
-
The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab.Front Immunol. 2019 Nov 19;10:2686. doi: 10.3389/fimmu.2019.02686. eCollection 2019. Front Immunol. 2019. PMID: 31803192 Free PMC article. Clinical Trial.
-
No association of AQP4 polymorphisms with neuromyelitis optica and multiple sclerosis.Transl Neurosci. 2016 Aug 22;7(1):76-83. doi: 10.1515/tnsci-2016-0012. eCollection 2016. Transl Neurosci. 2016. PMID: 28123825 Free PMC article.
-
Pediatric multiple sclerosis: current concepts and consensus definitions.Autoimmune Dis. 2013;2013:673947. doi: 10.1155/2013/673947. Epub 2013 Nov 2. Autoimmune Dis. 2013. PMID: 24294520 Free PMC article. Review.
-
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.Int J Mol Sci. 2020 Dec 24;22(1):100. doi: 10.3390/ijms22010100. Int J Mol Sci. 2020. PMID: 33374173 Free PMC article. Review.
LinkOut - more resources
Full Text Sources
